Trials / Unknown
UnknownNCT05547256
A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China
A Preliminary Exploratory Cohort Study to Evaluate Safety, Tolerability and Immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in Participants Aged 18 Years and Over in China
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- AIM Vaccine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a preliminary exploratory cohort study to evaluate safety, tolerability and immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in participants Aged 18 years and over in China
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose | 50μg/dose |
| BIOLOGICAL | COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose | 100μg/dose |
| DRUG | Placebo | Saline solution |
Timeline
- Start date
- 2022-09-13
- Primary completion
- 2022-12-05
- Completion
- 2024-03-01
- First posted
- 2022-09-21
- Last updated
- 2023-02-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05547256. Inclusion in this directory is not an endorsement.